# Immunoglobulin A Nephropathy; IgAN FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/immunoglobulin-a-nephropathy-igan

> 6 upcoming FDA catalysts in immunoglobulin A Nephropathy; IgAN: felzartamab (BIIB) on May to Aug 2027 (topline data readout); felzartamab (BIIB) on May 2027 (primary completion); ARGX-121 (ARGX) on Oct 2029 to Jan 2030 (topline data readout); ARGX-121 (ARGX) on October 2029 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 5, 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Immunoglobulin A Nephropathy; IgAN | completed | "NCT06291376 (Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06291376)) |
| May to Aug 2027 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT06935357 (A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06935357)) |
| May 2027 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT06935357 (A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06935357)) |
| Oct 2029 to Jan 2030 | [ARGX-121 topline data readout](https://sec-api.dev/pdufa/argx-121) | ARGX | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07773727 (A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-29 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07773727)) |
| October 2029 | [ARGX-121 primary completion](https://sec-api.dev/pdufa/argx-121) | ARGX | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07773727 (A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-29 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07773727)) |
| Jul to Oct 2030 | [Zigakibart topline data readout](https://sec-api.dev/pdufa/zigakibart) | NVS | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07146906 (A Study to Assess the Effects of Zigakibart on IgA Nephropathy.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-07-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07146906)) |
| July 2030 | [Zigakibart primary completion](https://sec-api.dev/pdufa/zigakibart) | NVS | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07146906 (A Study to Assess the Effects of Zigakibart on IgA Nephropathy.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-07-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07146906)) |

## Drugs

- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [ARGX-121](https://sec-api.dev/pdufa/argx-121) (ARGX)
- [Zigakibart](https://sec-api.dev/pdufa/zigakibart) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/immunoglobulin-a-nephropathy-igan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Immunoglobulin A Nephropathy; IgAN FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/immunoglobulin-a-nephropathy-igan

```bibtex
@misc{secapidev_indications_immunoglobulin_a_nephropathy_igan_20261116,
  title        = {Immunoglobulin A Nephropathy; IgAN FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/immunoglobulin-a-nephropathy-igan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_immunoglobulin_a_nephropathy_igan_20261116","title":"Immunoglobulin A Nephropathy; IgAN FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/immunoglobulin-a-nephropathy-igan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
